TORONTO, June 30 /CNW/ - Biosign Technologies Inc. (CNSX: BIO, Biosign) is pleased to announce it has retained the services of the following individuals to execute the Company's sales and marketing objectives in the Unites States of America (US) and internationally.
Robert Kaul, Executive Vice President. Mr. Kaul will be responsible for managing all US sales, marketing and operations activities for Biosign, and will also assist the Company with global marketing and fulfillment strategies. He was founder and CEO of Cloud Diagnostics LLC and has a 22-year track record as a senior manager of aggressive growth companies. Mr. Kaul will be based at Biosign's US office at 122 W 27th Street New York, NY.
Todd Frech, Director of Sales - Medical Informatics. Mr. Frech will be responsible for sales and marketing of the Company's products to the Biotech, Pharma and Electronic Health Record industries in the United States. Mr. Frech was a co-founder of Cloud Diagnostics LLC, and is a recognized authority on Health Informatics in the US, where he developed the very first Electronic Health Record system for American Express.
Steven Rose, PhD, Director of Sales- Clinical Research. Dr Rose will be responsible for business development and sales to Clinical Research Organizations. He earned his PhD in Chemistry and Biochemistry from University of Massachusetts at Amherst, holds two patents for medical diagnostic tests and has over 10 years of experience in marketing and business development to the Clinical Research industry.
Anthony Kaul, Director of Internet Marketing. Mr. Kaul is the founder and CEO of HigherBracket.ca, Canada's largest executive internet job board. He employs a team of fourteen programmers, data specialists and customer service experts in Vancouver BC and Kochi, India. Mr. Kaul will be responsible for executing the Company's global e-commerce and internet marketing strategies.
Biosign will continue to use a channel strategy for sales and fulfillment in the United States and elsewhere. The addition of these talented individuals will enable the company to maintain an active role in the implementation of its technology in the marketplace during the pivotal first stages of commercialization.
About Biosign Technologies Inc.
Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit www.biosign.com.
The CNSX has neither approved nor disapproved the contents of this press release.
SOURCE Biosign Technologies Inc.
For further information: For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 234, Email: firstname.lastname@example.org